Nuveen LLC Purchases Shares of 149,231 MeiraGTx Holdings PLC $MGTX

Nuveen LLC purchased a new stake in shares of MeiraGTx Holdings PLC (NASDAQ:MGTX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 149,231 shares of the company's stock, valued at approximately $1,012,000. Nuveen LLC owned about 0.19% of MeiraGTx as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of MGTX. Sanofi bought a new position in shares of MeiraGTx during the fourth quarter valued at $74,284,000. Woodline Partners LP bought a new position in shares of MeiraGTx in the 4th quarter worth $9,349,000. Invesco Ltd. lifted its holdings in shares of MeiraGTx by 1,628.7% in the 1st quarter. Invesco Ltd. now owns 350,401 shares of the company's stock worth $2,376,000 after purchasing an additional 330,131 shares in the last quarter. Readystate Asset Management LP grew its holdings in MeiraGTx by 59.6% during the first quarter. Readystate Asset Management LP now owns 189,598 shares of the company's stock worth $1,285,000 after buying an additional 70,768 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in MeiraGTx by 43.2% during the fourth quarter. Nuveen Asset Management LLC now owns 191,311 shares of the company's stock worth $1,165,000 after buying an additional 57,737 shares in the last quarter. Institutional investors own 67.48% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MGTX. Chardan Capital reiterated a "buy" rating and set a $35.00 price target on shares of MeiraGTx in a report on Friday, August 15th. Wall Street Zen raised shares of MeiraGTx from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $24.00.

MeiraGTx Trading Down 0.4%

Shares of NASDAQ MGTX traded down $0.03 during midday trading on Friday, hitting $7.69. 414,011 shares of the company traded hands, compared to its average volume of 298,228. The stock has a 50-day moving average price of $7.89 and a 200 day moving average price of $6.82. The company has a debt-to-equity ratio of 26.29, a quick ratio of 0.88 and a current ratio of 0.88. The firm has a market cap of $618.64 million, a P/E ratio of -3.77 and a beta of 1.29. MeiraGTx Holdings PLC has a 12-month low of $3.86 and a 12-month high of $8.98.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. The business had revenue of $3.69 million for the quarter, compared to the consensus estimate of $8.00 million. MeiraGTx had a negative return on equity of 314.44% and a negative net margin of 415.39%. As a group, analysts expect that MeiraGTx Holdings PLC will post -1.48 earnings per share for the current year.

Insider Buying and Selling at MeiraGTx

In other MeiraGTx news, CEO Alexandria Forbes sold 47,500 shares of MeiraGTx stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $7.97, for a total value of $378,575.00. Following the sale, the chief executive officer directly owned 1,361,483 shares in the company, valued at approximately $10,851,019.51. The trade was a 3.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Richard Giroux sold 24,000 shares of the stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $8.52, for a total transaction of $204,480.00. Following the transaction, the chief financial officer owned 853,494 shares of the company's stock, valued at $7,271,768.88. This trade represents a 2.74% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.50% of the company's stock.

MeiraGTx Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.